Ibex Celebrates a Decade of Clinical AI Leadership Following Its Latest Record-Setting Quarter Building Towards Another Year of Doubling Revenue
Ibex Medical Analytics (Ibex), the global pioneer in AI-powered pathology, today celebrates 10 years of clinical innovation. Ahead of the European Congress of Pathology (ECP) 2026, Ibex also launches Ibex Breast Lymph Node*, rounding out the industry’s most comprehensive, end-to-end Breast AI Suite, offering laboratories a unified workflow that seamlessly transitions from primary biopsy and excision review1-4 to IHC pre-ordering5 and IHC scoring across biopsies, resections and Lymph Nodes.
Over ten years of continuous innovation, Ibex has established itself as the leading provider of clinical-grade AI applications. Ibex has spent a decade developing highly accurate and robustly validated AI solutions. Ibex is the only independent computational pathology vendor with FDA clearance and holds numerous CE-IVDR certified solutions. Today, the company’s platform is backed by an extensive body of clinical evidence – demonstrated across numerous multi-center trials and peer-reviewed publications, and is proven daily in routine clinical practice at hundreds of live sites worldwide, analyzing 2.4 million slides per year with AI.